Neurology of ciguatera

J Pearn

Abstract
Ciguatera is a widespread ichthyosarco-toxaemia with dramatic and clinically important neurological features. This severe form of fish poisoning may present with either acute or chronic intoxication syndromes and constitutes a global health problem. Ciguatera poisoning is little known in temperate countries as a potentially global problem associated with human ingestion of large carnivorous fish that harbour the bioaccumulated ciguatoxins of the photosynthetic dinoflagellate Gambierdiscus toxicus. This neurotoxin is stored in the viscera of fish that have eaten the dinoflagellate and concentrated it upwards throughout the food chain towards progressively larger species, including humans. Ciguatoxin accumulates in all fish tissues, especially the liver and viscera, of “at risk” species. Both Pacific (P-CTX-1) and Caribbean (C-CTX-1) ciguatoxins are heat stable polyether toxins and pose a health risk at concentrations above 0.1 ppb. The presenting signs of ciguatera are primarily neurotoxic in more than 90% of cases. Such include the pathognomonic features of post-ingestion paraesthesiae, dysaesthesiae, and heightened nociception. Other sensory abnormalities include the subjective features of metallic taste, pruritis, arthralgia, myalgia, and dental pain. Cerebellar dysfunction, sometimes diphasic, and weakness due to both neuropathy and polymyositis may be encountered. Autonomic dysfunction leads to hypotension, bradycardia, and hypersalivation in severe cases. Ciguatoxins are potent, lipophilic sodium channel activator toxins which bind to the voltage sensitive (site 5) sodium channel on the cell membranes of all excitable tissues. Treatment depends on early diagnosis and the early administration of intravenous mannitol. The early identification of the neurological features in sentinel patients has the potential to reduce the number of secondary cases in cluster outbreaks.

(J Neurol Neurosurg Psychiatry 2001;70:4–8)

Keywords: ciguatera; fish poisoning; neurotoxins; public health

It was Galen who first said that Moray eels were dangerous to eat.1 When European colonists first settled in the islands of the Caribbean they encountered the neurological consequences suffered by gourmet victims who had ingested the local gastropod, Livona, called “ciguá”. It was thought that all cases were due to the ingestion of snails, although it is now appreciated that most were in fact due to the eating of ciguatoxic fish. Parra, in 1787 in his “Description de Diferents Piezas” in the Antilles, referred to the neurological symptoms of the clinical intoxication which he called “ciguatera”.1

The neurological manifestations of ciguatera are dramatic and often enigmatic. Ciguatoxins are some of the most potent biological toxins known. Their neurotropic effects produce a protean array of symptoms which are distressing in the acute phase syndrome and which are enervating throughout the often prolonged progression of convalescence.

The detailed neurological effects of ciguatera were first described by Surgeon Lieutenant William Anderson RN, naval surgeon on Cook’s Ship HMS Resolution, in the Pacific in 1786.2 Cook’s crew had caught fish which were eagerly eaten by the sailors and the scraps fed to the ship’s dogs. Anderson described the neurological features of the consequent severe intoxication in both human and canine victims. He described the distressing skin tingling, the “reversal” of tactile heat sensation, and the accompanying nausea and prostration.

Ciguatera is a clinical intoxication3,4 caused by the ingestion of ciguatoxic fish.5 Human victims are the end link in a food chain cascade.1 The primary toxins are manufactured in the benthic (bottom dwelling) dinoflagellate Gambierdiscus toxicus;3 and are concentrated successively in the flesh and viscera of small piscine herbivores, small carnivorous fish, and ultimately in larger fish, many species of which are prized gourmet species. “At risk” fish include some species of mackerel (Scomberomorus sp) and barracuda (Sphyraena sp) and many of the tropical reef species such as coral trout (Plectropomus sp); and in some parts of the world the fish and viscera of Moray eels (Lycodontis sp).6 The disease is not uncommon in many littoral populations of the tropical and subtropical nations of the world.6 In some island nations in the Caribbean and in the Pacific where the principal source of protein is fish, the annual incidence of...
intoxication may approach 10% of the population. Ciguatera poisoning is poorly understood as a potential global health problem in temperate countries, particularly in North America and Europe. The toxin is stored in the viscera of fish that have eaten the photosynthetic dinoflagellate; and is progressively concentrated upwards along the food chain. The toxin is stable in the tissue of living fish and does them no harm. Larger carnivores have higher concentrations of the toxin in their tissues. The practical consequence of this is that consumption of the largest carnivorous fish—often those gourmet specimens which are frozen and transported for intercontinental consumption—therefore forms the greatest risk of ciguatera intoxication for the consumer. Pacific ciguatoxins pose a health risk at concentrations (within ingested fish flesh) above 0.1 ppb.11

Extensive international commerce in frozen fish, and especially that involving trade in gourmet reef species, means that victims of this dramatic intoxication may now be encountered in all countries. An estimated 10 000–50 000 victims have the disease annually. Cases have been reported in the past decade from the United States (Hawaii14 and from Rhode Island15), Madagascar,16 Hong Kong,17 Europe,12 and extensively from the South Pacific.14 Ciguatera is thus a global health problem from the perspective of preventive medicine and an acute challenge for the clinician treating individual cases.

Increased awareness of the neurotoxic effects of ciguatera will aid in earlier diagnosis. This in turn will facilitate earlier treatment and the shortening of convalescence. The earlier identification of sentinel patients has the potential to prevent secondary cases and thus reduce the clinical clusters or micro-epidemics of victims.

Ciguatoxins
Ciguatoxins are potent heat stable, non-protein, lipophilic sodium channel activator toxins that bind quasi-irreversibly to the voltage sensitive sodium channel at site five.15 The molecular targets are found on all membranes of excitable tissues but with varying tissue specific affinity. The receptor site overlaps the receptor site for brevitoxin, another food chain paralytic toxin. Both Pacific and Caribbean ciguatoxin18 have as their basic structure unique molecular chains of 13 and 14 joined ether rings (C13H20O10) respectively. Nine of these transfused rings form a ladder which is very similar in all ciguatoxins (figure).11,11 The toxins are tasteless and odourless and are relatively heat stable to the temperatures usually employed in cooking. Both Pacific ciguatoxins (P-CTX-1) and Caribbean ciguatoxins (C-CTX-1) are stable for at least 6 months at commercial freezing temperatures.19

Clinical evidence suggests that the toxin binds to sodium channel receptor sites of both somatic and autonomic nerves. The chronicity of symptoms (months or years in some victims) and the exquisite sensitivity of convalescent victims accidentally subjected to rechallenge14 suggests that the sodium channel receptors are inactivated permanently; and that convalescence from severe intoxication may depend on the generation of new receptors.

Extensive experimental studies of Pacific ciguatoxins, using rat dissociated dorsal root ganglion neurons in whole cell patch clamp techniques, have shown that P-CTX-1 causes tetrodotoxin sensitive (TTX-S) sodium channels to open closer to their normal resting membrane potential. By contrast, tetrodotoxin resistant (TTX-R) sodium channels recover from inactivation more quickly, enabling earlier

Molecular structure of the Pacific (P-CTX-1) and the Caribbean (C-CTX-1) ciguatoxins. These toxins are heat stable polyether molecules of 1023–1157 Da and pose a health risk at concentrations above 0.1 ppb. Structure courtesy of Associate Professor Richard Lewis, University of Queensland, with acknowledgements.
Acute ciguatera: neurological symptoms and signs

The full syndrome of ciguatera involves neurological, musculoskeletal, dermatological, gastrointestinal, and psychological symptoms. The neurological symptoms, subjectively always the most distressing, are listed in the table.

Neurological features may include peripheral sensory or motor symptoms, central symptoms such as severe prolonged distressing headache, or autonomic features. In severe intoxications, autonomic dysfunction may present as bradycardia or hypotension.

Mortality is region specific, and in the case of the Pacific ciguatoxins is less than 0.5%. The pathognomonic symptoms of acute ciguatera poisoning are paraesthesiae and dysaesthesiae. The paraesthesiae spread centrifugally, dependent on ingested dose, from circumoral origins. The pathophysiological basis for the centrifugal spread of symptoms has not been determined. It has been proposed informally that this may be due to a disproportionate concentration of sodium channel receptors along the peripheral nerves; or may be due to a primary neurotoxic selectivity acting on the cell bodies of sensory nerves initially with subsequent intraneural spread of the toxin along both axons and dendrites. Several hours after consuming a fish meal, victims awake at night, perplexed and distressed. The paraesthesiae last for a minimum of several days and in severe cases persist for many weeks. The slow regression of such paraesthesiae often causes secondary anxiety or depressive symptoms. In my experience these secondary symptoms may be accentuated in victims who have been severely poisoned in miniepidemics; and who see themselves chronically ill by contrast and comparison with those who were mildly affected and who recovered from their perplexing symptoms within a few days of initial poisoning.

Ciguatoxic dysaesthesia is classically referred to as a “reversal of thermal sensation”. The best modern description of this pathognomonic symptom was that given by Bagnis who highlighted this feature in the Bulletin of the World Health Organisation in 1970 as a “paradoxical sensory disturbance”. The clinical features of ciguatera intoxication were the further subject of a detailed study in the United States Virgin Islands by Morris et al in 1982. In my experience the dysaesthesia of ciguatera is not a true reversal of thermal sensation. Rather, cold or even room temperature objects, when touched, produce a disagreeable burning sensation; and warm objects produce a sensation described variously by victims in such terms as “ice burning cold”, “chilled”, or “cold-sharp”. Warm fluids are particularly distressing and showering or bathing may be too painful to endure by some severely poisoned victims. I have seen adult cases with such heightened nociperception, especially to fluids, that victims are reduced to shocked weeping in the context of unbearable distress during muciturition or breast feeding. Cerebellar signs and a late presenting tremor are well described in the unpublished reports of victim support associations. Because these cerebellar signs may appear after the subsidence of paraesthesiae and are themselves self-limiting, they have not been reported in detail.

Chronic ciguatera: neurological features

The chronic effects of ciguatera have been recognised in Pacific littoral communities for centuries. Studies in the United States Virgin Islands showed that more than half of the victims poisoned by Caribbean ciguatoxins had chronic dysaesthesia with a median duration exceeding 2 weeks after initial poisoning. The intractable fatigue, experienced by some 3%-20% of severely intoxicated victims, is perplexing to patients and frustrating to doctors. The persistent fatigability and weakness is often accompanied by depression. It is not known whether the depression—which in some victims can be a major feature of the prostrating fatigability of chronic ciguatera—is due primarily to residual toxic effects, or secondary to the organic debilitation which may follow the primary episode of poisoning. In patients presenting with the constellation of symptoms

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraesthesiae</td>
<td>One of the first signs of ciguatera intoxication. Occurs within hours of toxic fish ingestion. Symptoms last for days or weeks. Centrifugal spread from circumoral and glossal focus.</td>
</tr>
<tr>
<td>Dyzaesthesia</td>
<td>A combination of hyperesthesia; heightened nociperception; peripheral dysaesthesiae with possible central element of perturbed sensation.</td>
</tr>
<tr>
<td>Other sensory signs</td>
<td>Metallic taste, pruritus, arthralgia, and myalgia.</td>
</tr>
<tr>
<td>Pain</td>
<td>Limb, skin, joints, dental, and urethral.</td>
</tr>
<tr>
<td>Headache</td>
<td>May be a presenting sign. Usually non-localised; may be intense and prolonged.</td>
</tr>
<tr>
<td>Weakness</td>
<td>Both peripheral features often with central accentuation due to prostration.</td>
</tr>
<tr>
<td>Autonomic signs</td>
<td>Hypersalivation, bradycardia, laryngeal spasm, hypotension, mydriasis, or mesosisis.</td>
</tr>
<tr>
<td>Sensory signs</td>
<td>Insomnia, vertigo, nightmares (especially zoopsia), coma, convulsions.</td>
</tr>
<tr>
<td>Motor symptoms and signs</td>
<td>Weakness (due to both neural involvement and polynuromy) and hyporeflexia; dysphagia, paresis.</td>
</tr>
<tr>
<td>Cerebellar signs and tremor</td>
<td>Sometimes late presenting; may occur up to 10 days after initial intoxication.</td>
</tr>
</tbody>
</table>

Table 1: Acute neurological symptoms and signs seen by ciguatera victims
and signs which comprise the chronic fatigue syndrome it is always important to include the possibility of chronic ciguatera in the differential diagnosis. In rare cases ciguatera may cause peripheral neuropathy and polymyositis.

The insomnia of the acute ciguatera syndrome may gradually change into the hyper-somnia which is a common feature of chronic ciguatera, and is cognate to that experienced by victims of chronic fatigue syndrome. In cases of chronic fatigue syndrome in which ciguatera can confidently be established as the cause, there is no need indeed it is counterproductive to embark on open ended extensive investigations and a continuum of pathological tests. A milieu of optimism with confidence about the success of long term convalescence, is the best approach during long term clinical surveillance of such victims over ensuing months.

Differential diagnosis
The ichthyosarcotoxaemias include maiktotoxaemia, fugu (tetrodotoxin poisoning), scombroid (histamine) fish poisoning, clupeoid poisoning, elasmobranch (shark liver) poisoning, mercury fish poisoning, and bacterial fish despolishment. None has the peculiar dramatic features of dyssyasthesiae so characteristic in some 80% of victims of ciguatera. Fugu may produce rapid onset paraesthesiae and a generalised numbness with the subjects describing a feeling of “floating on air”—a transient state which may progress to life threatening acute paralysis. Clupeoid poisoning may follow the eating of herring-like fish and presents with abdominal pain, itching, coma, and convulsions. Scombroid poisoning (histamine poisoning) may follow the eating of spoiled tuna, bonito, mackerel, and skipjack. Scombroid or histamine fish poisoning is now the most prevalent form of seafood borne disease in the United States. Histamine production in these stored fish is a consequence of the free histidine content of the fresh fish which is broken down by the bacterial enzyme histidine decarboxylase. The most common symptoms of scombroid poisoning include flushing, urticaria, hypotension, and headache—always associated with vomiting, diarrhoea, and abdominal cramps. Itching may be intense and be associated with urticarial lesions.

Currently there is no secure, commercially pragmatic test for ciguatoxins in fish flesh. The traditional method of detecting the presence of ciguatoxins in fish flesh involves testing lipid extracts by mouse bioassay. Recent research has shown that cytotoxicity, radioligand binding, and antibody based methods have the potential to be developed into cost effective screens for ciguatoxic fish at the market place or restaurant. The toxin is so potent that high performance liquid chromatography and mass spectroscopy are not sufficiently sensitive to detect clinically relevant concentrations of ciguatoxin in crude extracts of fish. Bioassays are available in various research centres. The diagnosis is essentially a clinical one, made particularly in the context of a detailed history of the type of fish species ingested, the rate of onset of symptoms, and a knowledge of the characteristic neurological features.

Nerve conduction studies may be abnormal. In experimental animals neurophysiological studies have demonstrated slowing of both mixed and motor nerve conduction velocities with reduction of depolarisation amplitudes. It is important to appreciate that many toxins produce dyssyasthesiae as an important “sentinel” symptom of clinical poisoning. In the context of differential diagnosis, paraesthesia is a non-specific feature in itself and the point should clearly be made that both sodium ion channel “openers” (for example, ciguatoxin, pyrethroids) and sodium ion channel “closers” (for example, tetrodotoxin and the clinical syndrome of fugu poisoning) produce similar, early onset “sentinel” circunoral distribution of paraesthesia.

Treatment
Hyperosmotic mannitol infusions may reduce Schwann cell oedema which is a feature of acute ciguatera. Although not yet tested by double blind trials, most case series report that more than 60% of victims have their symptoms reversed by mannitol infusion provided that this is administered within 48 hours of the onset of symptoms. No other therapy, other than non-specific supportive management, has been shown to be of benefit. The neurological symptoms, however chronic, always resolve gradually. Some 5% of severely intoxicated victims complain of residual symptoms, particularly overwhelming chronic fatigue, for many months or even years after the acute episode.

Lipid storage and slow release of toxin has been proposed as the basis for the persistence and recurrent nature of the symptoms. Many victims report that relapses are triggered by other agents such as alcohol. However, it is known that relapse of symptoms may be initiated by the ingestion of chicken or pig meats from commercially raised animals which have been fed on fish meal; with the implication that such commercial feedstocks contain ciguatoxins in otherwise subclinical concentrations.

Intravenous mannitol infusion is the only therapy known to reverse the sensory symptoms and autonomic signs of ciguatera. The dose of mannitol which is recommended is 10 ml/kg of the standard 20% solution, infused slowly over not less than 30–45 minutes. If dehydration has developed due to vomiting as part of the acute phase syndrome, this should be corrected before mannitol infusion is instituted. If symptoms are reduced, a second dose can be given within 3–4 hours; and repeated on the next day. The pharmacological basis for the use of mannitol remains speculative. Its effect is thought to be due to osmotic reduction of neuronal oedema, but a “scavenger” property of the molecule has been suggested. No ill effects have yet been reported from its use and I have not experienced ill effects from its use in personal unpublished cases. There is no accumulated
evidence to suggest that the blood-brain barrier is opened to larger concentrations of ciguatoxin. The pleomorphic nature of ciguatera, the subjectivity of many of its symptoms in the absence of any definitive laboratory diagnosis for clinical cases make this condition one of the most challenging in clinical medicine.

I thank Dr Christopher Gardner-Thorpe, Consultant Neurologist of Exeter; Associate Professor Richard Lewis of the Centre for Drug Design, the University of Glasgow, for much encouragement. For Drug Design, the University of Queensland, Brisbane; and Associate Professor Richard Lewis of the Centre for Drug Design, the University of Queensland, Brisbane; and Associate Professor Richard Lewis of the Centre for Drug Design, the University of Queensland, Brisbane; and Assistant Professor Robert Papp, School of Public Health, University of Queensland, for much encouragement. Assistant Professor Robert Papp, School of Public Health, University of Queensland, for much encouragement. For Drug Design, the University of Queensland, Brisbane; and Assistant Professor Robert Papp, School of Public Health, University of Queensland, for much encouragement.